Eton Pharmaceutical (US.ETON)
Capital Allocation Audit · Period: 2018 – 2026
Key Metrics
US.ETON · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | -103.6% | ↓ |
| ROE | 5.1% | ↑ |
| Cash Conversion | 476.5% | → |
| D/E Ratio | 1.02 | ↑ |
| Gross Margin | 60.7% | ↑ |
US.ETON (Eton Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ----------------------------- FCF Conversion -103.6% ↓ ROE 5.1% ↑ Cash Conversion 476.5% → D/E Ratio 1.02 ↑ Gross Margin 60.7% ↑
Key Metrics
US.ETON (Eton Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY-----------------------------FCF Conversion -103.6% ↓ROE 5.1% ↑Cash Conversion 476.5% →D/E Ratio 1.02 ↑Gross Margin 60.7% ↑Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies